Revonto® (dantrolene sodium for injection)

For More information on Malignant Hyperthermia please visit The Malignant Hyperthermia Association of the United States (MHAUS).

Home / What is Malignant Hyperthermia (MH)? / About Revonto / Frequently Asked Questions / Ordering Information / Contact Us
Full Prescribing Information / Clinical Pharmacology / Indications and Usage / Dosage and Administration / How Revonto is Supplied
Privacy Policy / Terms of Use / US WorldMeds Home

Important Safety Information

Revonto is indicated, along with appropriate supportive measures, for the management of fulminant hypermetabolism of skeletal muscle characteristic of malignant hyperthermia crises in patients of all ages. It is also indicated preoperatively and sometimes postoperatively, to prevent or attenuate the development of clinical and laboratory signs of malignant hyperthermia in individuals judged to be malignant hyperthermia susceptible. Malignant hyperthermia is life threatening and requires immediate medical attention and treatment. Fatal and non-fatal liver disorders of an idiosyncratic or hypersensitivity type may occur with dantrolene sodium therapy. There have been reports of thrombophlebitis following administration of intravenous dantrolene. There have been rare reports of urticaria and erythema possibly associated with the administration of i.v. dantrolene sodium.

CONTRAINDICATIONS: None.

For additional information, see full prescribing information for Revonto.